Use of trifunctional bispecific antibodies for the treatment of tumors associated with CD133+/EpCAM+cancer stem cells

Details for Australian Patent Application No. 2010238472 (hide)

Owner TRION Pharma GmbH

Inventors Lindhofer, Horst

Agent Freehills

Pub. Number AU-A-2010238472

PCT Pub. Number WO2010/119119

Priority 09158179.3 17.04.09 EP

Filing date 16 April 2010

Wipo publication date 21 October 2010

International Classifications

C07K 16/28 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C07K 16/30 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C07K 16/46 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies - Hybrid immunoglobulins

Event Publications

20 October 2011 PCT application entered the National Phase

  PCT publication WO2010/119119 Priority application(s): WO2010/119119

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010238473-Method and device for connecting a photovoltaic system to an alternating-current network

2010238466-Low power active matrix display